このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Feasibility and Effectiveness of an AI-Powered Carbohydrate Counting Educational Platform to Support Parents of Children With Type 1 Diabetes (CARB-AI)

2026年6月26日 更新者:Dr. Hussain Al Saffar、Sultan Qaboos University

Feasibility and Effectiveness of an AI-Powered Carbohydrate Counting Educational Platform to Support Parents of Children With Type 1 Diabetes: A Multicentre Randomized Controlled Trial

The goal of this clinical trial is to learn whether an AI-powered carbohydrate counting educational platform can help parents of children with type 1 diabetes improve their carbohydrate counting skills and diabetes management. The study will include parents or primary caregivers of children aged 2-12 years with type 1 diabetes.

The main questions it aims to answer are:

  • Is the AI-powered educational platform feasible, acceptable, and easy for parents to use?
  • Can the platform improve carbohydrate counting accuracy, parental confidence in diabetes management, and diabetes outcomes compared with usual education alone?

Researchers will compare parents who receive access to the AI-powered carbohydrate counting educational platform plus usual diabetes education with parents who receive usual diabetes education alone to see whether the AI-supported approach provides additional benefits.

Participants will:

  • Complete baseline assessments, including questionnaires and a carbohydrate counting test.
  • Be randomly assigned to either the AI-supported education group or the usual education group.
  • Use the assigned educational resources for 12 weeks.
  • Complete a follow-up assessment at 6 weeks and a final assessment at 12 weeks.
  • Provide information about their child's diabetes management, including HbA1c and glucose monitoring data.
  • Complete questionnaires about confidence, usability, and satisfaction with the educational support they receive.

The AI platform is designed to provide educational support only and does not replace medical advice, insulin dosing decisions, or routine diabetes care provided by healthcare professionals.

調査の概要

状態

まだ募集していません

条件

詳細な説明

This multicentre randomized controlled feasibility trial will evaluate an AI-powered educational platform designed to support carbohydrate counting education for parents of children with type 1 diabetes (T1D). Accurate carbohydrate counting is an essential component of T1D management because insulin dosing is closely linked to carbohydrate intake. However, many parents experience challenges in estimating carbohydrate content accurately, which may affect glycemic control.

The intervention uses conversational artificial intelligence to provide personalized educational support, interactive learning opportunities, and practical guidance related to carbohydrate counting. The platform is intended as an educational tool and does not provide medical advice or insulin dosing recommendations. Educational content and safety oversight are provided by pediatric endocrinologists, diabetes educators, and registered dietitians.

The primary objective of this feasibility study is to evaluate recruitment, retention, participant engagement, intervention adherence, and data collection procedures to determine whether a future definitive efficacy trial is warranted. Secondary objectives include assessment of participant acceptability and usability, as well as exploration of preliminary effects on carbohydrate counting accuracy, parental diabetes management self-efficacy, and glycemic outcomes.

Participants will be recruited from our pediatric diabetes centers, and randomized to receive either access to the AI-powered educational platform in addition to enhanced usual care or enhanced usual care alone. Study findings will inform the development of larger trials evaluating the role of conversational artificial intelligence in diabetes education and chronic disease self-management.

研究の種類

介入

入学 (推定)

80

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究連絡先のバックアップ

  • 名前:Hussain Alsaffar, FACE, MSc, FRCPCH
  • 電話番号:+96896399402
  • メール:hussaina@squ.edu.om

研究場所

      • Dubai、アラブ首長国連邦
        • Al Jalila Children's Hospital
      • Sharjah city、アラブ首長国連邦
        • Al Qasimi Hospital
      • Muscat、オマーン、123
        • Sultan Qaboos University Hospital

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 子
  • 大人
  • 高齢者

健康ボランティアの受け入れ

いいえ

説明

Inclusion Criteria:

  • Primary responsibility for carbohydrate counting and insulin dosing decisions for the child
  • English-speaking
  • Access to a smartphone (iOS or Android) with internet connectivity
  • Willing and able to provide informed consent and complete study procedures
  • Diagnosis of type 1 diabetes for at least 1 month
  • Receiving intensive insulin therapy (multiple daily injections or insulin pump)
  • Using carbohydrate counting for insulin dosing

Exclusion Criteria:

  • Child has significant developmental delay or a medical condition that substantially alters nutritional requirements or carbohydrate metabolism (e.g., celiac disease, cystic fibrosis)
  • Parent or caregiver has significant cognitive impairment that would preclude participation
  • Family plans to relocate from the study area during the study period
  • Participation in another diabetes intervention study

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:支持療法
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:独身

武器と介入

参加者グループ / アーム
介入・治療
実験的:AI-Powered Carbohydrate Counting Educational Platform + Enhanced Usual Care
Participants receive access to an AI-powered carbohydrate counting educational platform in addition to enhanced usual diabetes care. The platform provides interactive educational support, carbohydrate counting practice, personalized feedback, scenario-based learning, and educational guidance under dietitian and diabetes specialist oversight. Participants also receive standard diabetes education materials and routine clinical care for 12 weeks.
Participants will receive access to an AI-powered carbohydrate counting educational platform designed for parents of children with type 1 diabetes. The platform provides interactive carbohydrate counting education, personalized educational guidance, carbohydrate estimation practice, natural-language question answering, and scenario-based learning. Participants will use the platform for 12 weeks in addition to enhanced usual diabetes care. All educational content is developed and supervised by pediatric endocrinologists, certified diabetes educators, and registered dietitians. The platform functions as an educational support tool only and does not provide medical advice or insulin dosing recommendations.
介入なし:Enhanced Usual Care Alone
Participants receive enhanced usual diabetes care consisting of standard diabetes education provided by their clinical care team, printed carbohydrate counting educational materials, portion size reference materials, educational PDF resources, and routine clinical care. Participants do not receive access to the AI-powered carbohydrate counting educational platform

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Recruitment Rate
時間枠:12 months
Number and proportion of eligible participants recruited into the study across participating sites.
12 months
Retention Rate
時間枠:12 weeks
Proportion of enrolled participants who complete the 12-week follow-up assessment.
12 weeks
Intervention Adherence
時間枠:12 weeks
Proportion of participants in the intervention group who engage with the AI-powered carbohydrate counting educational platform for at least 10 sessions during the study period.
12 weeks
Data Completeness
時間枠:12 weeks
Proportion of participants with complete primary outcome data collected at baseline and 12-week follow-up assessments.
12 weeks

二次結果の測定

結果測定
メジャーの説明
時間枠
Acceptability of Intervention Measure
時間枠:12 weeks
Participant-rated acceptability of the AI-powered carbohydrate counting educational platform using the validated 4-item Acceptability of Intervention Measure.
12 weeks
Carbohydrate Counting Accuracy
時間枠:Baseline and 12 weeks
Change in carbohydrate counting accuracy assessed using a standardized carbohydrate counting assessment. Accuracy will be defined as the percentage of estimates within 20% of dietitian-calculated carbohydrate values.
Baseline and 12 weeks
Time in Range (70-180 mg/dL)
時間枠:Baseline and 12 weeks
Percentage of time glucose values remain within the target range of 70-180 mg/dL based on continuous glucose monitoring or glucose meter data.
Baseline and 12 weeks
Glucose Variability
時間枠:Baseline and 12 weeks
Change in glucose variability measured by coefficient of variation of glucose values.
Baseline and 12 weeks
System Usability Scale
時間枠:12 weeks
Participant-rated usability of the AI-powered carbohydrate counting educational platform measured using the System Usability Scale (SUS), a validated 10-item questionnaire. The SUS total score ranges from 0 to 100, with higher scores indicating better perceived usability.
12 weeks
Net Promoter Score
時間枠:12 weeks
Participant likelihood of recommending the AI-powered carbohydrate counting educational platform to other parents of children with type 1 diabetes, measured using the Net Promoter Score (NPS). Participants rate their likelihood of recommending the platform on a scale from 0 (Not at all likely) to 100 (Extremely likely). Higher scores indicate a greater likelihood of recommending the intervention.
12 weeks

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • スタディチェア:Moez AlIslam Faris, PhD、Applied Science Private University

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年9月1日

一次修了 (推定)

2027年8月31日

研究の完了 (推定)

2027年12月31日

試験登録日

最初に提出

2026年6月22日

QC基準を満たした最初の提出物

2026年6月22日

最初の投稿 (実際)

2026年6月26日

学習記録の更新

投稿された最後の更新 (実際)

2026年6月30日

QC基準を満たした最後の更新が送信されました

2026年6月26日

最終確認日

2026年6月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する